Business context and reporting period
Integra LifeSciences Holdings Corporation filed this Form 8-K on October 9, 2026, to disclose pricing of a debt issuance. This is a financing update, not a report of operating results for a fiscal period.
Key financial and financing information
- The company priced $450 million aggregate principal amount of 9.500% senior secured notes due 2033 in a private placement.
- Management expects the notes, together with other anticipated elements of its debt refinancing, to increase the company’s effective interest rate by near the high end of the previously communicated 100–200 basis-point range.
- The filing provides no updated revenue, profit, cash flow, margin, liquidity, or total debt figures. It also does not state the refinancing’s other terms or the notes’ expected proceeds after fees.
Changes, outlook, and risks
The disclosed financing indicates that the anticipated borrowing-cost increase is expected to be near the top of management’s prior range. The filing does not provide further refinancing details or an operating outlook. Forward-looking statements are subject to risks and uncertainties, including those described in the company’s 2025 Form 10-K and subsequent SEC filings.
Important facts for investors to verify
- Final terms and closing status of the notes, including any conditions and use of proceeds.
- Terms of the other refinancing components and the resulting effective interest rate and annual interest expense.
- Updated debt, liquidity, and covenant information in subsequent company disclosures.